A Phase IIa Trial of sEphB4-HSA in Combination With Anti PD-1 Antibody (Pembrolizumab, MK3475) in Patients With Non-small Cell Lung and Head/Neck Cancer
Latest Information Update: 20 Mar 2024
At a glance
- Drugs Pembrolizumab (Primary) ; SEphB4-HSA (Primary)
- Indications Carcinoma; Head and neck cancer; Non-small cell lung cancer
- Focus Therapeutic Use
- 14 Mar 2024 Planned End Date changed from 10 Mar 2025 to 10 Mar 2026.
- 14 Mar 2024 Planned primary completion date changed from 10 Mar 2024 to 10 Mar 2025.
- 18 Nov 2022 Planned End Date changed from 10 Mar 2024 to 10 Mar 2025.